Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS)

This study has been completed.
ALS Association
University of Kansas
Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System
Information provided by:
The University of Texas Health Science Center at San Antonio Identifier:
First received: July 27, 2005
Last updated: March 13, 2012
Last verified: March 2012

The purpose of this study is to determine the safety and efficacy of Myobloc in ALS patients who are having excessive drooling.

The primary goal of the study is to determine if the patient perceives a benefit from the Myobloc in controlling excessive drooling.

Condition Intervention Phase
Amyotrophic Lateral Sclerosis
Drug: Botulinum toxin type B (Myobloc)
Procedure: Injection of salivary glands
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis

Resource links provided by NLM:

Further study details as provided by The University of Texas Health Science Center at San Antonio:

Primary Outcome Measures:
  • Global impression of change by subject at eight weeks post injection

Secondary Outcome Measures:
  • Patient's subjective assessment of benefit
  • Change in volume of saliva produced over five minutes (measured with funnel and tube)
  • ALS Functional Rating Scale (ALSFRS)
  • Caregiver's subjective assessment of benefit
  • Change in anticholinergic medication doses and number of times per day suction is used
  • Duration of benefit
  • Assessment of treatment assignment (final visit only)
  • Global assessment of change by investigator

Estimated Enrollment: 20
Study Start Date: July 2003
Study Completion Date: August 2007
Detailed Description:

The secondary goals of this study are to:

  • determine the safety of bilateral injections of Myobloc into the parotid and submandibular glands as an effort to control sialorrhea;
  • determine by objective measures if the Myobloc injection decreases the saliva produced;
  • determine caregiver perceived benefit from Myobloc injection.

Ages Eligible for Study:   21 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of probable or definite ALS based on current World Federation of Neurology criteria
  • Between the ages of 21-85, inclusive
  • Sialorrhea refractory to treatment with at least two anticholinergic medications OR has been intolerant of anticholinergic medications due to side effects
  • Capable of giving informed consent
  • Must be able to attend all study visits

Exclusion Criteria:

  • Patient has any uncontrolled significant medical, psychiatric or neurological disease (other than ALS) over the past 30 days
  • History of ongoing substance abuse
  • History of non-compliance with treatment in other experimental protocols
  • Cannot provide informed consent or comply with evaluation procedures
  • Has received any form of botulinum toxin in the past for any indication
  • Women who are pregnant, lactating, or of child bearing potential not using an adequate form of birth control
  • Currently being treated with coumadin
  • Forced vital capacity (FVC) <40% of predicted unless the tidal volume is > 600cc, as patients with significant bulbar weakness may show a falsely low FVC due to bulbar muscle spasticity
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00125203

United States, Kansas
University of Kansas Medical Center/Neurology, 1008 Wescoe
Kansas City, Kansas, United States, 66160-7314
United States, North Carolina
Carolinas MDA Neuromuscular/ALS Center; Carolinas Medical System; 1540 Garden Terrace
Charlotte, North Carolina, United States, 28203
Sponsors and Collaborators
The University of Texas Health Science Center at San Antonio
ALS Association
University of Kansas
Carolinas MDA Neuromuscular/ALS Center-Carolinas Medical System
Principal Investigator: Carlayne E Jackson, MD The University of Texas Health Science Center at San Antonio
Principal Investigator: Charles B Simpson, MD The University of Texas Health Science Center at San Antonio
  More Information

No publications provided Identifier: NCT00125203     History of Changes
Other Study ID Numbers: BB-IND 11090
Study First Received: July 27, 2005
Last Updated: March 13, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by The University of Texas Health Science Center at San Antonio:
Amyotrophic Lateral Sclerosis
Lou Gehrig's Disease
Motor Neuron Disease
Excessive Drooling
botulinum toxin type B
Clostridium botulinum B toxin
botulinum B toxin
botulinum neurotoxin B

Additional relevant MeSH terms:
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Central Nervous System Diseases
Metabolic Diseases
Mouth Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neuromuscular Diseases
Pathologic Processes
Proteostasis Deficiencies
Salivary Gland Diseases
Spinal Cord Diseases
Stomatognathic Diseases
TDP-43 Proteinopathies
Botulinum Toxins
Botulinum Toxins, Type A
Anti-Dyskinesia Agents
Central Nervous System Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on March 03, 2015